Flower City Capital’s Outlook Therapeutics OTLK Stock Holding History

Flower City Capital’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$31.8K	Hold	20,000	–	–	0.01%	49
2026 Q1	$4.12K	Hold	20,000	–	–	﹤0.01%	46
2025 Q4	$31.6K	Hold	20,000	–	–	0.02%	44
2025 Q3	$21.2K	Buy	+20,000	New	+$34.6K	0.01%	43
2024 Q1	–	Sell	-1,500	Closed	-$11.8K	–	35
2023 Q4	$11.8K	Hold	1,500	–	–	0.01%	35
2023 Q3	$6.63K	Sell	1,500 -1,000	-40%	-$22.1K	0.01%	29
2023 Q2	$87K	Sell	2,500 -201	-7%	-$5.48K	0.1%	28
2023 Q1	$58.9K	Hold	2,701	–	–	0.07%	26
2022 Q4	$58.3K	Buy	2,701 +112	+4%	+$2.44K	0.07%	26
2022 Q3	$63K	Hold	2,589	–	–	0.09%	27
2022 Q2	$53K	Buy	2,589 +1,589	+159%	+$45.7K	0.05%	29
2022 Q1	$36K	Buy	+1,000	New	+$31.2K	0.03%	31

Other funds holding OTLK

CKAIS

Christensen King & Associates Investment Services Richland, Washington $252M AUM 20.51% 1-Year Est. Return

OFS

Orrstown Financial Services Harrisburg, Pennsylvania $674M AUM 23.23% 1-Year Est. Return

FTWA

Fifth Third Wealth Advisors Cincinnati, Ohio $3.58B AUM 34.55% 1-Year Est. Return

GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return

AAG

Armstrong Advisory Group Needham, Massachusetts $1.64B AUM 19.37% 1-Year Est. Return

Flower City Capital's OTLK Position: Q2 2026 in Review

Flower City Capital held its Outlook Therapeutics (OTLK) position steady in Q2 2026 at 20,000 shares worth $31.8K. The position accounts for 0.01% of the portfolio, ranked #49.

Flower City Capital first reported a position in OTLK in Q1 2022 and has held it in 12 quarters since. The position peaked at $87K in Q2 2023. 6 funds tracked by Wall St. Rank hold OTLK as of Q2 2026.

Flower City Capital held 20,000 shares of Outlook Therapeutics worth $31.8K as of Q2 2026.
Flower City Capital left its Outlook Therapeutics share count unchanged in Q2 2026.
Outlook Therapeutics made up 0.01% of Flower City Capital's portfolio in Q2 2026, its #49 holding.
Flower City Capital first reported a position in Outlook Therapeutics in Q1 2022 and has held it in 12 quarters since.
Flower City Capital's Outlook Therapeutics position peaked at $87K in Q2 2023.
6 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2026.

Based on Flower City Capital's 13F filing for Q2 2026, filed 7 Jul 2026.